Seegene, Inc. (096530.KQ)
KRW 23550.0
(-1.26%)
KRW 23550.0
(-1.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 180.07 Billion KRW | -61.37% |
| 2022 | 466.14 Billion KRW | -55.97% |
| 2021 | 1058.73 Billion KRW | 25.63% |
| 2020 | 842.71 Billion KRW | 1075.66% |
| 2019 | 71.68 Billion KRW | 18.91% |
| 2018 | 60.28 Billion KRW | 8.19% |
| 2017 | 55.71 Billion KRW | 20.36% |
| 2016 | 46.29 Billion KRW | 12.8% |
| 2015 | 41.03 Billion KRW | -12.37% |
| 2014 | 46.82 Billion KRW | 6.97% |
| 2013 | 43.77 Billion KRW | 24.72% |
| 2012 | 35.1 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 39.75 Billion KRW | -27.84% |
| 2024 Q2 | 52.28 Billion KRW | 31.52% |
| 2023 Q2 | 39.46 Billion KRW | -1.86% |
| 2023 Q1 | 40.2 Billion KRW | -44.19% |
| 2023 FY | 180.07 Billion KRW | -61.37% |
| 2023 Q4 | 55.09 Billion KRW | 21.62% |
| 2023 Q3 | 45.3 Billion KRW | 14.8% |
| 2022 Q3 | 21.52 Billion KRW | -73.66% |
| 2022 Q2 | 81.7 Billion KRW | -71.92% |
| 2022 Q4 | 72.04 Billion KRW | 234.73% |
| 2022 Q1 | 290.98 Billion KRW | -9.78% |
| 2022 FY | 466.14 Billion KRW | -55.97% |
| 2021 Q1 | 263.37 Billion KRW | -21.64% |
| 2021 Q3 | 203.8 Billion KRW | -5.47% |
| 2021 FY | 1058.73 Billion KRW | 25.63% |
| 2021 Q4 | 322.51 Billion KRW | 58.25% |
| 2021 Q2 | 215.59 Billion KRW | -18.14% |
| 2020 Q1 | 60.97 Billion KRW | 202.84% |
| 2020 Q3 | 254.03 Billion KRW | 22.97% |
| 2020 Q4 | 336.08 Billion KRW | 32.3% |
| 2020 FY | 842.71 Billion KRW | 1075.66% |
| 2020 Q2 | 206.58 Billion KRW | 238.78% |
| 2019 FY | 71.68 Billion KRW | 18.91% |
| 2019 Q3 | 21.6 Billion KRW | 7.61% |
| 2019 Q4 | 20.13 Billion KRW | -6.79% |
| 2019 Q2 | 20.07 Billion KRW | 3.06% |
| 2019 Q1 | 19.47 Billion KRW | 0.79% |
| 2018 Q1 | 15.81 Billion KRW | -12.97% |
| 2018 FY | 60.28 Billion KRW | 8.19% |
| 2018 Q4 | 19.32 Billion KRW | 20.02% |
| 2018 Q3 | 16.1 Billion KRW | -1.82% |
| 2018 Q2 | 16.4 Billion KRW | 3.68% |
| 2017 Q3 | 14.49 Billion KRW | 4.69% |
| 2017 Q2 | 13.84 Billion KRW | 0.46% |
| 2017 Q1 | 13.78 Billion KRW | -0.88% |
| 2017 Q4 | 18.17 Billion KRW | 25.41% |
| 2017 FY | 55.71 Billion KRW | 20.36% |
| 2016 FY | 46.29 Billion KRW | 12.8% |
| 2016 Q1 | 12.13 Billion KRW | -0.4% |
| 2016 Q2 | 13.32 Billion KRW | 9.79% |
| 2016 Q3 | 13.07 Billion KRW | -1.89% |
| 2016 Q4 | 13.9 Billion KRW | 6.37% |
| 2015 Q2 | 10.98 Billion KRW | -9.09% |
| 2015 Q1 | 12.08 Billion KRW | 5.98% |
| 2015 Q4 | 12.18 Billion KRW | 6.1% |
| 2015 FY | 41.03 Billion KRW | -12.37% |
| 2015 Q3 | 11.48 Billion KRW | 4.5% |
| 2014 Q1 | 11.99 Billion KRW | -3.05% |
| 2014 FY | 46.82 Billion KRW | 6.97% |
| 2014 Q4 | 11.4 Billion KRW | 3.74% |
| 2014 Q3 | 10.99 Billion KRW | -11.59% |
| 2014 Q2 | 12.43 Billion KRW | 3.72% |
| 2013 Q4 | 12.36 Billion KRW | 7.34% |
| 2013 Q2 | 11.03 Billion KRW | 24.58% |
| 2013 FY | 43.77 Billion KRW | 24.72% |
| 2013 Q3 | 11.52 Billion KRW | 4.42% |
| 2013 Q1 | 8.85 Billion KRW | -12.4% |
| 2012 Q4 | 10.11 Billion KRW | 25.0% |
| 2012 Q3 | 8.08 Billion KRW | 0.0% |
| 2012 FY | 35.1 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 18.06% |
| InBody Co.,Ltd | 128.11 Billion KRW | -40.556% |
| Curexo Inc. | 17.95 Billion KRW | -902.832% |
| i-SENS, Inc. | 101.04 Billion KRW | -78.216% |
| Ray Co., Ltd. | 65.08 Billion KRW | -176.658% |
| Gencurix Inc. | 422.03 Million KRW | -42567.63% |
| Sugentech Inc. | -5.88 Billion KRW | 3161.991% |
| L&C Bio Co., Ltd | 32.52 Billion KRW | -453.6% |